Appointment of Non-Executive Director

18 August 2015

LSE: VER

Vernalis plc - Appointment of Non-Executive Director

Vernalis plc announces that Ms Lisa Amster Schoenberg, aged 48, has been appointed to the Board as a Non-Executive Director with effect from 1 September 2015.

Ms Schoenberg has extensive marketing experience of pharmaceutical products in both primary and secondary care in the US. For the past two years, she has acted as pharmaceutical marketing consultant to a number of organisations. From 1993 until 2013 Ms Schoenberg worked for AstraZeneca Pharmaceuticals (US) in a number of senior marketing positions, culminating as VP Sales & Marketing, Growth Brands USA. After graduating from the University of Michigan in 1988, Ms Schoenberg joined Amster & Co as Financial Analyst. She then undertook an MBA at Wharton School, University of Pennsylvania, specialising in Healthcare Management and Marketing, before joining AstraMerck in 1993.

Peter Fellner, Chairman of Vernalis plc, commented:

"I am delighted to welcome Lisa to the Vernalis Board. Her experience in launching and commercialising products in the US market in both primary care and speciality medicines and her knowledge of the changing US marketing environment and how it is likely to evolve will be invaluable for the Board. We look forward to her contribution, as we continue to build value for Vernalis' shareholders."

Disclosures:

Ms Schoenberg is a trustee of the Shipley School and currently on the board of directors of the Jewish Family & Children Services Philadelphia.

There is no other information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Ms Schoenberg's appointment with effect from 1 September 2015 as a Non-Executive Director of the Company.

-- ends --

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

For further information about Vernalis, please visit www.vernalis.com.